Cargando…
Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk)
BACKGROUND: Gliomas represent a biologically heterogeneous group of primary brain tumors with uncontrolled cellular proliferation and diffuse infiltration that renders them almost incurable, thereby leading to a grim prognosis. Recent comprehensive genomic profiling has greatly elucidated the molecu...
Autores principales: | Rathore, Saima, Mohan, Suyash, Bakas, Spyridon, Sako, Chiharu, Badve, Chaitra, Pati, Sarthak, Singh, Ashish, Bounias, Dimitrios, Ngo, Phuc, Akbari, Hamed, Gastounioti, Aimilia, Bergman, Mark, Bilello, Michel, Shinohara, Russell T, Yushkevich, Paul, O’Rourke, Donald M, Sloan, Andrew E, Kontos, Despina, Nasrallah, MacLean P, Barnholtz-Sloan, Jill S, Davatzikos, Christos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829474/ https://www.ncbi.nlm.nih.gov/pubmed/33521638 http://dx.doi.org/10.1093/noajnl/vdaa128 |
Ejemplares similares
-
Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma
por: Fathi Kazerooni, Anahita, et al.
Publicado: (2020) -
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016) -
Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010) -
Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020) -
Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)